Oncopeptides AB
STO:ONCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oncopeptides AB
STO:ONCO
|
SE |
|
B
|
Bunge Ltd
BMV:BG
|
US |
|
Intercos SpA
MIL:ICOS
|
IT |
|
R
|
Raspberry Pi Holdings PLC
LSE:RPI
|
UK |
|
A
|
Accenture PLC
BMV:ACNN
|
IE |
|
Stoneridge Inc
NYSE:SRI
|
US |
|
E
|
Executive Network Partnering Corp
NYSE:GRNT
|
US |
|
C
|
Canasil Resources Inc
XTSX:CLZ
|
CA |
|
Information Services Corp
TSX:ISV
|
CA |
|
Replicel Life Sciences Inc
XTSX:RP
|
CA |
|
CarrefourSA Carrefour Sabanci Ticaret Merkezi AS
IST:CRFSA.E
|
TR |
Oncopeptides AB
Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
